Lupin Ltd.

Lupin Ltd. surged to a fresh 52-week high of Rs 2249.3 on 3 Feb 2026, marking a robust intraday performance with a gain of 5.67% from the previous close. The pharmaceutical giant’s stock demonstrated strong buying interest throughout the session, outperforming the broader Sensex and its sector peers.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, reached a new 52-week high of Rs.2249.3 today, underscoring a notable rally and positive momentum in its stock performance. This milestone reflects the company’s sustained strength amid a dynamic market environment.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating adjusted from Strong Buy to Buy as of 28 January 2026. This change reflects a nuanced reassessment across four critical parameters: quality, valuation, financial trend, and technicals. While the company continues to demonstrate robust fundamentals and attractive valuation metrics, evolving technical indicators have prompted a more cautious stance among analysts.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a slight dip in its share price, the stock continues to demonstrate resilience with mixed signals from key technical indicators such as MACD, RSI, and moving averages, suggesting a complex but cautiously optimistic outlook for investors.

Lupin Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Despite a modest day decline of 1.29%, the stock’s technical indicators, including MACD, RSI, and moving averages, suggest strengthening price momentum that could underpin future gains amid broader market challenges.

Lupin Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Buy to Strong Buy as of 23 January 2026. This upgrade reflects significant improvements across four key parameters: quality, valuation, financial trend, and technicals. The company’s strong financial performance, attractive valuation metrics, and bullish technical indicators have collectively driven this positive reassessment, positioning Lupin as a compelling investment opportunity amid a challenging market backdrop.

Lupin Ltd., a major player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 22.3% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest decline in the stock price, this spike in OI alongside volume patterns suggests evolving directional bets that merit close attention from market participants.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a slight dip in the stock price, the increase in open interest by 18.25% suggests growing speculative interest and potential directional bets ahead.

Lupin Ltd., a major player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased market participation and potential directional bets. The stock’s recent price action, combined with evolving volume patterns and market positioning, offers valuable insights into investor sentiment and future prospects.

Lupin Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 Nov 2025. While the rating change occurred then, the analysis and financial metrics presented here reflect the stock's current position as of 20 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Lupin Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 Nov 2025. While the rating was assigned on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Lupin Ltd. demonstrated robust intraday strength on 7 Jan 2026, surging to an intraday high of Rs 2,225.25, marking a 3.41% increase from its previous close. This performance outpaced the Pharmaceuticals & Biotechnology sector and the broader market indices, underscoring the stock’s strong momentum amid a mixed market backdrop.

Lupin Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock has outperformed its sector peers and the broader market, reflecting growing investor confidence amid robust volume and price action.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting heightened market activity and bullish investor sentiment. The stock has outperformed its sector peers and the broader market, supported by robust volume and rising investor participation, signalling potential directional bets on further price appreciation.

Lupin Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting heightened investor interest and potential directional bets. The stock outperformed its sector and broader indices, supported by robust volume and rising investor participation, signalling a positive market sentiment heading into early 2026.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock has outperformed its sector peers, supported by robust volume and rising investor interest, reflecting a bullish sentiment among traders and investors alike.